作者
Vadim Makarov,Giulia Manina,Katarı́na Mikušová,Ute Möllmann,O. B. Ryabova,Brigitte Saint‐Joanis,Neeraj Dhar,Maria Rosalia Pasca,Silvia Buroni,Anna Lucarelli,Anna Milano,Edda De Rossi,Martina Beláňová,Adela Bobovská,Petronela Dianišková,Jana Korduláková,Claudia Sala,Elizabeth Fullam,Patricia Schneider,John D. McKinney,Priscille Brodin,Thierry Christophe,Simon J. Waddell,Philip D. Butcher,Jakob Albrethsen,Ida Rosenkrands,Roland Brosch,Vrinda Nandi,Bharath Srinivasan,Sheshagiri Gaonkar,Radha Krishan Shandil,V. Balasubramanian,Tanjore S. Balganesh,Sandeep Tyagi,J Grosset,Giovanna Riccardi,Stewart T. Cole
摘要
Ammunition for the TB Wars Tuberculosis is a major human disease of global importance resulting from infection with the air-borne pathogen Mycobacterium tuberculosis , which is becoming increasingly resistant to all available drugs. An antituberculosis benzothiazinone compound kills mycobacterium in infected cells and in mice. Makarov et al. (p. 801 ) have identified a sulfur atom and nitro residues important for benzothiazinone's activity and used genetic methods and biochemical analysis to identify its target in blocking arabinogalactan biosynthesis during cell-wall synthesis. The compound affects the same pathway as ethambutol, and thus a benzothiazinone drug has the potential to become an important part of treatment of drug-resistant disease and, possibly, replace the less effective ethambutol in the primary treatment of tuberculosis.